THE REAL A2M CONCENTRATOR - CAREstream Physician Regenerative Network
post-template-default,single,single-post,postid-16075,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive


With the rapid advances occurring in the Regenerative Medicine space, it can be difficult to decipher which are quality products and not an imitation, promising sub par results. There is only one system on the market that ISOLATES and CONCENTRATES Alpha-2-Macroglobulin (A2M), and that is the Cytonics APIC-A2M System.

While any blood-based system will include trace amounts of A2M, it will not deliver A2M in therapeutic quantities to mitigate cartilage destruction long term. APIC’s patented technology isolates and concentrates A2M with yields ~6 times the amount found in blood and in any other system.

The majority of A2M research has been spearheaded by the leadership of Cytonics and Dr. Gaetano Scuderi. They have shown that the efficacy of A2M for protease inhibition and subsequent pain relief is dose dependent. Unlike hemoconcentrators, which only remove water from the sample, APIC’s patented process uses tangential flow filter technology to remove pro-inflammatory cytokines, smaller proteins, and water to maximize the A2M dose and isolate it from catabolic factors that would otherwise result in a net zero improvement

As the exclusive distributor of the Cytonics APIC-A2M system, Catalyst continues to provide the highest quality products for the best value. If you’re serious about alternatives to standard treatment algorithms, talk to Catalyst about adding APIC-A2M to your regenerative medicine program.